TY - JOUR T1 - Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial JF - Lancet Y1 - 2015 A1 - E J Lawitz A1 - E J Gane A1 - Pearlman, B. A1 - et, al VL - 385 SP - 1075-1086 IS - 9973 ER -